179 related articles for article (PubMed ID: 29288321)
1. RASSF1A promoter methylation was associated with the development, progression and metastasis of cervical carcinoma: a meta-analysis with trial sequential analysis.
Zheng F; Yu H
Arch Gynecol Obstet; 2018 Feb; 297(2):467-477. PubMed ID: 29288321
[TBL] [Abstract][Full Text] [Related]
2. Hypermethylation of two consecutive tumor suppressor genes, BLU and RASSF1A, located at 3p21.3 in cervical neoplasias.
Lai HC; Lin YW; Chang CC; Wang HC; Chu TW; Yu MH; Chu TY
Gynecol Oncol; 2007 Mar; 104(3):629-35. PubMed ID: 17097722
[TBL] [Abstract][Full Text] [Related]
3. Association between RASSF1A Promoter Hypermethylation and Oncogenic HPV Infection Status in Invasive Cervical Cancer: a Meta-analysis.
Li JY; Huang T; Zhang C; Jiang DJ; Hong QX; Ji HH; Ye M; Duan SW
Asian Pac J Cancer Prev; 2015; 16(14):5749-54. PubMed ID: 26320446
[TBL] [Abstract][Full Text] [Related]
4. The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix.
Cohen Y; Singer G; Lavie O; Dong SM; Beller U; Sidransky D
Clin Cancer Res; 2003 Aug; 9(8):2981-4. PubMed ID: 12912945
[TBL] [Abstract][Full Text] [Related]
5. Alterations of RASSF1A in premalignant cervical lesions: clinical and prognostic significance.
Mitra S; Mazumder Indra D; Basu PS; Mondal RK; Roy A; Roychoudhury S; Panda CK
Mol Carcinog; 2012 Sep; 51(9):723-33. PubMed ID: 21809394
[TBL] [Abstract][Full Text] [Related]
6. Methylation of the hsa-miR-124, SOX1, TERT, and LMX1A genes as biomarkers for precursor lesions in cervical cancer.
Rogeri CD; Silveira HCS; Causin RL; Villa LL; Stein MD; de Carvalho AC; Arantes LMRB; Scapulatempo-Neto C; Possati-Resende JC; Antoniazzi M; Longatto-Filho A; Fregnani JHTG
Gynecol Oncol; 2018 Sep; 150(3):545-551. PubMed ID: 29960712
[TBL] [Abstract][Full Text] [Related]
7. Assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens.
Kim JH; Choi YD; Lee JS; Lee JH; Nam JH; Choi C
Gynecol Oncol; 2010 Jan; 116(1):99-104. PubMed ID: 19836067
[TBL] [Abstract][Full Text] [Related]
8. Aberrant promoter methylation can be useful as a marker of recurrent disease in patients with cervical intraepithelial neoplasia grade III.
Terra AP; Murta EF; Maluf PJ; Caballero OL; Brait M; Adad SJ
Tumori; 2007; 93(6):572-9. PubMed ID: 18338492
[TBL] [Abstract][Full Text] [Related]
9. Quantitative assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens.
Kim JH; Choi YD; Lee JS; Lee JH; Nam JH; Choi C; Kweon SS; Fackler MJ; Sukumar S
Virchows Arch; 2010 Jul; 457(1):35-42. PubMed ID: 20496080
[TBL] [Abstract][Full Text] [Related]
10. TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia.
Steenbergen RD; Kramer D; Braakhuis BJ; Stern PL; Verheijen RH; Meijer CJ; Snijders PJ
J Natl Cancer Inst; 2004 Feb; 96(4):294-305. PubMed ID: 14970278
[TBL] [Abstract][Full Text] [Related]
11. [Quantitative detection of APC/RASSF1A promoter methylation in the plasma of patients with cervical diseases].
Wang H; Pan SY; Pang ZR; Wang F; Xu J; Chen D; Xie EF; Zhang LX; Gao L; Xu YQ; Jin B
Zhonghua Fu Chan Ke Za Zhi; 2013 Dec; 48(12):929-34. PubMed ID: 24495688
[TBL] [Abstract][Full Text] [Related]
12. [Promoter methylation of DAPK1, RAR-β and MGMT in exfoliated cervical cytology and its clinical application].
Zhong ZJ; Yang JX; Cao DY; Sun Y; Sun LL; Cheng XM; Chen J; Lang JH; Shen K
Zhonghua Fu Chan Ke Za Zhi; 2012 Mar; 47(3):196-200. PubMed ID: 22781071
[TBL] [Abstract][Full Text] [Related]
13. CDH1 promoter methylation in patients with cervical carcinoma: a systematic meta-analysis with trial sequential analysis.
Liu G
Future Oncol; 2018 Jan; 14(1):51-63. PubMed ID: 29237293
[TBL] [Abstract][Full Text] [Related]
14. Prediction of human papillomavirus 16 e6 gene expression and cervical intraepithelial neoplasia progression by methylation status.
Hublarova P; Hrstka R; Rotterova P; Rotter L; Coupkova M; Badal V; Nenutil R; Vojtesek B
Int J Gynecol Cancer; 2009 Apr; 19(3):321-5. PubMed ID: 19407553
[TBL] [Abstract][Full Text] [Related]
15. Associations between methylation of paternally expressed gene 3 (PEG3), cervical intraepithelial neoplasia and invasive cervical cancer.
Nye MD; Hoyo C; Huang Z; Vidal AC; Wang F; Overcash F; Smith JS; Vasquez B; Hernandez B; Swai B; Oneko O; Mlay P; Obure J; Gammon MD; Bartlett JA; Murphy SK
PLoS One; 2013; 8(2):e56325. PubMed ID: 23418553
[TBL] [Abstract][Full Text] [Related]
16. Methylation of the RASSF1A gene promoter in Uigur women with cervical squamous cell carcinoma.
Pan Z; Li J; Pan X; Chen S; Wang Z; Li F; Qu S; Shao R
Tumori; 2009; 95(1):76-80. PubMed ID: 19366060
[TBL] [Abstract][Full Text] [Related]
17. [Clinical significance of detection of tumor suppressor genes aberrant methylation in cervical carcinoma tissue].
Xu J; Wang HL; Lu GC; Wang ZJ; Lin X; Zhou HW
Zhonghua Fu Chan Ke Za Zhi; 2007 Jun; 42(6):394-7. PubMed ID: 17697601
[TBL] [Abstract][Full Text] [Related]
18. HPV16 oncogenes E6 or/and E7 may influence the methylation status of RASSFIA gene promoter region in cervical cancer cell line HT-3.
Yin F; Wang N; Wang S; Yu F; Sun X; Yu X; Luo B; Zhao C; Wang Y
Oncol Rep; 2017 Apr; 37(4):2324-2334. PubMed ID: 28260046
[TBL] [Abstract][Full Text] [Related]
19. Effect of aberrant promoter methylation of FHIT and RASSF1A genes on susceptibility to cervical cancer in a North Indian population.
Neyaz MK; Kumar RS; Hussain S; Naqvi SH; Kohaar I; Thakur N; Kashyap V; Das BC; Husain SA; Bharadwaj M
Biomarkers; 2008 Sep; 13(6):597-606. PubMed ID: 18608185
[TBL] [Abstract][Full Text] [Related]
20. Cervical cancer risk in HPV-positive women after a negative FAM19A4/mir124-2 methylation test: A post hoc analysis in the POBASCAM trial with 14 year follow-up.
De Strooper LMA; Berkhof J; Steenbergen RDM; Lissenberg-Witte BI; Snijders PJF; Meijer CJLM; Heideman DAM
Int J Cancer; 2018 Sep; 143(6):1541-1548. PubMed ID: 29663363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
